New York State Teachers Retirement System Sells 1,840 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

New York State Teachers Retirement System trimmed its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 7.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,280 shares of the specialty pharmaceutical company’s stock after selling 1,840 shares during the period. New York State Teachers Retirement System owned about 0.11% of ANI Pharmaceuticals worth $1,232,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. KBC Group NV lifted its stake in shares of ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the last quarter. HighTower Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $222,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of ANI Pharmaceuticals by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 1,582 shares during the last quarter. Finally, James Investment Research Inc. purchased a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $243,000. 76.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on ANIP. HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price for the company. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $57.94 on Monday. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a 50-day simple moving average of $57.08 and a 200 day simple moving average of $58.20. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market capitalization of $1.22 billion, a PE ratio of -105.35 and a beta of 0.74.

Insider Buying and Selling

In related news, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,781 shares of company stock worth $2,465,372. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.